Clinical Trial Update: Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 targeted CD19 CAR-T therapy trial for autoimmune diseases has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myopathies
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CD19 CAR-T therapy (CD19-targeted CAR-T cell therapy)

Snippet

Sponsor: Nanjing Bioheng Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis | EARLY_Phase 1 | Status: SUSPENDED